DefiniGEN
Parkwalk closes DefiniGEN investment for the University of Cambridge Enterprise Fund II
DefiniGEN provides human liver cells for preclinical drug development and disease modelling applications using human Induced Pluripotent Stem Cell hIPSC technology.
The Company provides human cells to the drug discovery sector for use in lead optimization and toxicity programmes. The Company’s proprietary production platform OptiDIFF robustly generates human cell types including liver hepatocytes using hIPSC human Induced Pluripotent Stem Cell technology.
Horizon Discovery
Horizon Discovery named in the Deloitte Tech Fast 50 2013
Omega Diagnostics
Omega Diagnostics: ‘majority’ of CD4 manufacturing variants eliminated
Horizon Discovery
Horizon Discovery: License Agreement agreed for Zinc Finger Nuclease Gene Editing Technology
Horizon Discovery
Secures landmark deal with Hisun Pharmaceuticals
A Cambridge UK pioneer in technology that will accelerate development of personalised medicines has secured a multi-million pound landmark deal with a Chinese pharmaceuticals giant….
Omega Diagnostics
Parkwalk closes Omega Diagnostic plc investment
Omega Diagnostics is focused on selling a wide range of specialist products, primarily in the immunoassay, in-vitro diagnostics (IVD) market within three segments: Allergy and Autoimmune, Food Intolerance and Infectious Disease.
The company aims to improve human health and well being through innovative diagnostic tests and global partnerships.
Sphere Fluidics
Wins ACES award for academic spin-outs
University of Cambridge spin-out Sphere Fluidics was among the winners at the ACES awards – the only pan-European awards for academic spin-outs – held earlier this week in Brussels.
Horizon Discovery
Parkwalk closes investment in Horizon Discovery for the University of Cambridge Enterprise Fund I
Horizon’s basic science and translational research knowledge deployed in combination with best-in-class translational genomics platforms, products and services provides meaningful solutions to the challenges of translational researchers.
Horizon aspires to provide solutions that unlock the promise of the human genome project for the benefit of scientific researchers, patients and society; provide powerful research tools to advance the development of personalized medicines; provide molecular reference standards and support better healthcare outcomes for patients.
Sphere Fluidics
Parkwalk closes Sphere Fluidics investment for the University of Cambridge Enterprise Fund I
Sphere Fluidics has developed unique products for use in single cell analysis and characterisation and provides collaborative R&D services.
A novel technology platform (called Cyto-MineTM) enables ultra-high throughput analysis of single cells and generation of their genetic, transcriptomic and proteomic profiles in miniaturised (pl to nl) volumes called picodroplets.
DefiniGEN
Parkwalk closes DefiniGen investment for the University of Cambridge Enterprise Fund I
DefiniGEN provides human cells to the drug discovery sector for use in lead optimization and toxicity programmes.
The Company’s proprietary production platform OptiDIFF robustly generates human cell types including liver hepatocytes using hIPSC human Induced Pluripotent Stem Cell technology.
Reinnervate
Parkwalk closes Reinnervate investment for the UK Tech Fund II
Reinnervate is a market leading company in the fast growing 3D cell culture market.
The alvetex® family of 3D cell culture products provides a flexible platform that allows technicians to quickly and easily establish better in vitro assays and models that better mimic in the in vivo growth of cells.
